[Form 4] Outset Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marc Nash, SVP Operations and R&D and director of Outset Medical (OM), reported a non-discretionary sell-to-cover transaction on 08/15/2025. He sold 243 shares of Outset common stock at $12.88 per share to satisfy tax withholding related to the vesting of an aggregate 673 restricted stock units granted on March 15, 2023, July 24, 2023, and January 12, 2024. After the transaction, the reporting person beneficially owned 42,898 shares directly. The Form 4 was signed by John L. Brottem on behalf of Marc Nash on 08/18/2025.

This filing is a routine insider tax-withholding sale and the filer states it was not a discretionary trade.

Insights

Securities Analyst

TL;DR: Routine sell-to-cover of vested RSUs; no indication of discretionary insider selling.

The disclosed sale of 243 shares at $12.88 was executed solely to satisfy tax withholding on 673 vested RSUs from grants in 2023 and 2024. The report shows a direct beneficial ownership of 42,898 shares after the transaction, which suggests the insider retains substantial equity alignment with shareholders. There are no indications of additional open-market trading or a broader disposition program in this filing.

Corporate Governance Expert

TL;DR: Transaction appears compliant and procedural; documentation includes required explanation and signature.

The Form 4 includes the required explanatory note that the sale was to cover tax withholding and includes a dated signature by an authorized filer. From a governance perspective, this is a routine disclosure fulfilling Section 16 reporting obligations and does not, by itself, raise red flags about disclosure practices or insider conduct.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nash Marc

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Operations and R&D

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S		243(1)	D	$12.88	42,898	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 673 shares of Common Stock underlying RSUs granted to the reporting person on March 15, 2023, July 24, 2023, and January 12, 2024. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

	By: John L Brottem For: Marc Nash	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marc Nash (OM) report on Form 4?

He reported a sell-to-cover of 243 shares at $12.88 on 08/15/2025 to satisfy tax withholding from vested RSUs.

How many RSU shares vested that triggered the sell-to-cover?

An aggregate of 673 RSUs vested from grants dated 03/15/2023, 07/24/2023, and 01/12/2024.

How many Outset (OM) shares does the reporting person own after the transaction?

The Form 4 reports 42,898 shares beneficially owned following the reported transaction.

Was the sale a discretionary trade by the insider?

No. The filing states the sale was executed to satisfy tax withholding obligations and does not represent a discretionary trade.

When was the Form 4 signed and filed?

The signature block shows filing by John L. Brottem for Marc Nash on 08/18/2025.